BOLD Valuation

Boundless Bio Inc

Add to Watchlist

Advanced Chart

1.170

+0.03(2.632%)1D

Overview
Forecast
Valuation
Earnings

BOLD Relative Valuation

BOLD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BOLD is overvalued; if below, it's undervalued.

Historical Valuation

Boundless Bio Inc (BOLD) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.11. The fair price of Boundless Bio Inc (BOLD) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：1.17

Fair

-0.46

Trailing

Forward

0.77

EV/EBITDA

Boundless Bio Inc. (BOLD) has a current EV/EBITDA of 0.77. The 5-year average EV/EBITDA is -0.33. The thresholds are as follows: Strongly Undervalued below -5.11, Undervalued between -5.11 and -2.72, Fairly Valued between 2.06 and -2.72, Overvalued between 2.06 and 4.46, and Strongly Overvalued above 4.46. The current Forward EV/EBITDA of 0.77 falls within the Historic Trend Line -Fairly Valued range.

0.82

EV/EBIT

Boundless Bio Inc. (BOLD) has a current EV/EBIT of 0.82. The 5-year average EV/EBIT is -0.18. The thresholds are as follows: Strongly Undervalued below -4.93, Undervalued between -4.93 and -2.55, Fairly Valued between 2.20 and -2.55, Overvalued between 2.20 and 4.57, and Strongly Overvalued above 4.57. The current Forward EV/EBIT of 0.82 falls within the Historic Trend Line -Fairly Valued range.

0.00

Boundless Bio Inc. (BOLD) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

-0.42

P/OCF

Boundless Bio Inc. (BOLD) has a current P/OCF of -0.42. The 5-year average P/OCF is -0.92. The thresholds are as follows: Strongly Undervalued below -3.11, Undervalued between -3.11 and -2.01, Fairly Valued between 0.17 and -2.01, Overvalued between 0.17 and 1.26, and Strongly Overvalued above 1.26. The current Forward P/OCF of -0.42 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Boundless Bio Inc. (BOLD) has a current P/FCF of 0.00. The 5-year average P/FCF is -1.19. The thresholds are as follows: Strongly Undervalued below -3.63, Undervalued between -3.63 and -2.41, Fairly Valued between 0.04 and -2.41, Overvalued between 0.04 and 1.26, and Strongly Overvalued above 1.26. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Boundless Bio Inc (BOLD) has a current Price-to-Book (P/B) ratio of 0.21. Compared to its 3-year average P/B ratio of 0.24 , the current P/B ratio is approximately -14.76% higher. Relative to its 5-year average P/B ratio of 0.24, the current P/B ratio is about -14.76% higher. Boundless Bio Inc (BOLD) has a Forward Free Cash Flow (FCF) yield of approximately -226.37%. Compared to its 3-year average FCF yield of -118.08%, the current FCF yield is approximately 91.70% lower. Relative to its 5-year average FCF yield of -118.08% , the current FCF yield is about 91.70% lower.

0.21

P/B

Median3y

0.24

Median5y

0.24

-220.41

FCF Yield

Median3y

-118.08

Median5y

-118.08

Competitors Valuation Multiple

The average P/S ratio for BOLD's competitors is 42.36, providing a benchmark for relative valuation. Boundless Bio Inc Corp (BOLD) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Cadrenal Therapeutics Inc

Sonnet Biotherapeutics Holdings Inc

21.75

23.44M

Performance Decomposition

Market capitalization of BOLD increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of BOLD in the past 1 year is driven by Unknown.